OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase I/II Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999
Date of occurrence of the event: Aug 31, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office Reciprocal shareholding ratios: Not …
Board of Directors Approved the Change of Financial Officer and Acting Spokesperson
Type of personnel changed (please enter: spokesperson, acting spokesperson, important perational officer, financial officer, accounting officer, company secretary, research and development officer, or internal audit officer): Financial officer and acting …
IND Phase I/II Human Clinical Trial Application of Globo-H Antibody-Drug Conjugate, OBI-999, submission to FDA
Date of occurrence of the event: Aug 03, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office Reciprocal shareholding ratios: Not …
Announcement on Change of Financial Officer and Acting Spokesperson
Type of personnel changed (please enter: spokesperson, acting spokesperson, important operational officer, financial officer, accounting officer, company secretary, research and development officer, or internal audit officer): Financial officer and acting …
Subsidiary AP Biosciences and Tasly Biopharmaceuticals Signed Cooperative Development and Authorized Agreement of New Antibody Drug
Date of occurrence of the event: Jul 29, 2019 Counterparty to the contract or commitment: Tasly Biopharmaceuticals Co. Ltd Relationship to the Company: None Starting and ending dates (or rescission …
Announcement on the Change of Spokesperson
Type of personnel changed (please enter: spokesperson, acting spokesperson, important operational officer, financial officer, accounting officer, company secretary, research and development officer, or internal audit officer): Spokesperson Date of occurrence …
Announcement of New CEO
Type of personnel changed (please enter: spokesperson, acting spokesperson, important operational officer, financial officer, accounting officer, company secretary, research and development officer, or internal audit officer): CEO Date of occurrence …
Announcement of 3rd Audit Committee Members
Date of occurrence of the change: Jul 22, 2019 Name of the functional committees: Audit Committee Name and resume of the replaced member: (1)Jerry G. Feng/ Director of Graduate Institute …
Announcement of 4th Payroll Committee Members
Date of occurrence of the change: Jul 22, 2019 Name of the functional committees: Payroll Committee Name and resume of the replaced member: (1)Jerry G. Feng/ Director of Graduate Institute …
OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL
OBI-3424 is a highly selective prodrug that is converted by aldo-keto reductase family 1 member C3 (AKR1C3) to a potent DNA-alkylating agent. OBI-3424 has entered clinical testing for hepatocellular carcinoma …